Clinicore
Frag 176-191 5mg – Research Peptide Vial | CLINICORE Peptides
Frag 176-191 5mg – Research Peptide Vial | CLINICORE Peptides
Couldn't load pickup availability
Frag 176-191 5mg Research Peptide Vial
Lyophilised Frag 176-191 supplied as a 5mg vial for controlled in-vitro research workflows.
CLINICORE Frag 176-191 5mg research peptide is supplied as a lyophilised solid in a single vial format for laboratory and analytical workflows. This Frag 176-191 peptide vial is intended for non-clinical in-vitro research environments where consistent presentation and documented handling are required.
Overview
Frag 176-191, also referred to as HGH Fragment 176-191, is a specialised research peptide used in controlled in-vitro studies relating to metabolism and endocrinology under non-clinical laboratory conditions.
Handling and solubility
This section provides Frag 176-191 handling guidance for laboratory workflows. Handle using appropriate laboratory PPE and standard laboratory safety procedures.
Due to the presence of hydrophobic amino acid sequences, this peptide may appear cloudy after reconstitution. This is normal and does not affect research quality.
Storage guidelines
These Frag 176-191 storage guidelines apply to lyophilised research peptides. Follow the CLINICORE reconstitution and storage instructions supplied on the website to maintain stability.
Intended use
This Frag 176-191 research peptide is supplied strictly for laboratory research use only. It is not for human or veterinary use and is not approved for clinical, diagnostic, or therapeutic applications.
CLINICORE quality and assurance
CLINICORE Peptides manufactures research materials through controlled synthesis processes designed to deliver high purity and batch consistency. Each Frag 176-191 batch undergoes internal identity and appearance checks prior to release.
If additional documentation is required for internal QC or research records, please contact the CLINICORE team prior to use so we can advise what information may be available.
Share
